WP4 PTJA03 on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)” is now available
23 January 2018
The EUnetHTA JA 2 has received funding from the European Union, in the framework of the Health Programme.